- Market Capitalization, $K 313,087
- Shares Outstanding, K 25,579
- Annual Sales, $ 0 K
- Annual Income, $ -4,630 K
- 60-Month Beta 1.47
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 10.99
|Period||Period Low||Period High||Performance|
| || |
+4.39 (+56.07%)since 12/21/20
| || |
+3.31 (+37.15%)since 10/21/20
| || |
+4.33 (+54.88%)since 01/21/20
Tech Stocks Lead Market Higher to Begin Short Week
S&P, NASDAQ Move Higher for Second Straight Session
First Positive Session of 2021
As of late, it has definitely been a great time to be an investor in Cassava Sciences (SAVA).
, /PRNewswire/ -- Thanks in large part to the global COVID-19 pandemic, 2020 has been a year of tremendous challenges and adversity. But those historic challenges have also been met with impressive resiliency...
The EC approves Pacira's (PCRX) Exparel for treating post-operative pain in adults and as a field block for treating somatic post-operative pain from small- to medium-sized surgical wounds in adults.
OptiNose (OPTN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.
Zoetis (ZTS) gets marketing authorization for Librela, for monthly alleviation of osteoarthritis pain in dogs.
Jazz Pharmaceuticals (JAZZ) reports better-than-expected third-quarter 2020 earnings and revenues and ups its sales guidance for 2020.
|Cassava Sciences Inc|
|Oppenheimer Russell 2000 Multifactor ETF|
|Micro-Cap Ishares ETF|
|Ishares Factors US Small Blend Style ETF|
|Russell 2000 Value Ishares ETF|
|Russell 2000 Value Vanguard|
|3rd Resistance Point||14.62|
|2nd Resistance Point||13.95|
|1st Resistance Point||13.10|
|1st Support Level||11.58|
|2nd Support Level||10.91|
|3rd Support Level||10.06|